rs6798347: Understanding Genetic Clopidogrel Responsiveness
The rs6798347 variant is a genetic marker located in the promoter region of the P2RY12 gene, which plays a role in platelet function. Research has identified this variant as being associated with variations in how individuals respond to the antiplatelet medication clopidogrel.
What each genotype means
Typical clopidogrel response
This genotype is associated with standard responsiveness to clopidogrel in studies of diverse populations. Because individual drug response is complex and influenced by many factors, please discuss your medication plan and any concerns about treatment efficacy with your clinician or pharmacist.
This genotype is common in many global populations, though exact frequencies vary significantly by ancestry.
Variable clopidogrel response
Research indicates this variant is associated with differences in how individuals respond to clopidogrel, highlighting the importance of transethnic genetic studies in cardiovascular care. As this is a complex trait, please consult your healthcare provider or pharmacist to discuss how your genetic profile may relate to your specific medication therapy.
This genotype is observed at varying frequencies across different ancestral groups, reflecting the diverse nature of this genetic marker.
Variable clopidogrel response
This genotype has been identified in studies investigating genetic factors that influence clopidogrel responsiveness. Because clinical response to medication is influenced by both genetic and non-genetic factors, you should discuss your treatment options and any questions regarding drug efficacy with your doctor or pharmacist.
This genotype is found in various populations, with its prevalence differing depending on the specific ancestral background of the population studied.
What is rs6798347?
The rs6798347 variant is a single nucleotide polymorphism (SNP) located in the promoter region of the P2RY12 gene. In genetics, a promoter region is a segment of DNA that acts as a control switch, determining how much of a specific protein is produced by a gene. Because this SNP is situated in a regulatory area rather than within the protein-coding sequence itself, it is thought to influence the expression levels of the P2RY12 receptor. This receptor is critical for platelet activation and aggregation, which are the processes that lead to blood clotting. By altering the activity of this gene, the variant may influence how sensitive an individual's platelets are to inhibitory signals, which is a key factor in the efficacy of certain cardiovascular medications.
Association with Clopidogrel Response
Clopidogrel is a widely used medication designed to prevent blood clots by inhibiting the P2Y12 receptor on platelets. Scientific studies, including recent research in diverse populations, have investigated whether specific genetic variants influence how well this drug works. The rs6798347 variant has been identified in some studies as a potential marker for clopidogrel responsiveness. Specifically, some evidence suggests that certain genotypes at this location are associated with a lower incidence of high on-treatment platelet reactivity (HTPR), a condition where platelets remain more active than desired despite medication. While these findings are statistically significant in specific study cohorts, the evidence is considered moderate. It is important to note that drug response is a complex, polygenic trait, meaning it is influenced by many different genes, environmental factors, and other medications, rather than a single genetic switch.
Understanding the Evidence
The association between rs6798347 and clopidogrel response highlights the importance of transethnic genetic studies. Because genetic backgrounds vary significantly across the globe, a variant that shows a strong effect in one population may show a different or negligible effect in another. Current research emphasizes that while rs6798347 is a candidate for influencing platelet reactivity, it is not the sole determinant of how a patient will respond to therapy. Most of the variability in drug response remains unexplained by any single SNP. Consequently, clinicians rely on a combination of clinical factors, such as age, weight, and other health conditions, alongside genetic information when making treatment decisions. The field of pharmacogenomics continues to evolve, and findings like these are essential for building a more comprehensive understanding of personalized medicine.
What You Can Do With This Information
If you have information about your genotype for rs6798347, it is important to view it as one small piece of a much larger puzzle. Genetic testing results should never be used to make independent decisions about your medication, such as stopping or changing the dose of a prescribed drug. If you are taking clopidogrel or are concerned about your response to antiplatelet therapy, the most appropriate step is to discuss your concerns with your cardiologist or primary care physician. They can interpret your genetic data within the context of your full medical history and current clinical guidelines. Pharmacists are also excellent resources for understanding how genetic variants might interact with your specific treatment plan. Always prioritize professional medical advice over individual genetic reports when managing your health.
How common is this variant?
The frequency of the rs6798347 variant is variable and depends significantly on ancestral background, with some studies noting significant differences in allele distribution across diverse populations.
Frequently asked questions
Does rs6798347 mean I will not respond to clopidogrel?
No. Genetic variants like rs6798347 are only one factor in how your body processes medication. Many other genes and clinical factors also play a role, and this variant does not guarantee a specific response to the drug.
Should I get tested for this SNP before taking medication?
Routine testing for this specific SNP is not currently standard clinical practice. You should follow the guidance of your healthcare provider, who will determine the best approach for your specific medical needs.
Can I change my clopidogrel dose based on my genotype?
Absolutely not. Never adjust your medication dosage or stop taking a prescribed drug without consulting your doctor. Doing so can be dangerous and may increase your risk of serious health events.
Where can I find more information on pharmacogenomics?
Resources like PharmGKB and MedlinePlus Genetics provide reliable, evidence-based information on how genes affect drug response. These sites are excellent for learning more about the science behind pharmacogenomics.
Sources & further reading
Educational information only, last refreshed 10/3/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6798347?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants
This variant is a significant risk factor for the development of Gaucher disease and Parkinson's disease.
This variant is associated with cystic fibrosis, affecting chloride channel function in epithelial cells.
This variant is a known pathogenic mutation contributing to hereditary breast and ovarian cancer syndrome.
This pathogenic variant is strongly associated with an increased lifetime risk of breast and ovarian cancer.
A polymorphism identified as a predictive biomarker for clopidogrel response in a multi-gene NGS panel study.
A sex-specific genetic locus on chromosome 11 associated with chronic pain in males.